Dicot Pharma
0.35 SEK
+0.57 %
Less than 1K followers
DICOT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+0.57 %
-22.11 %
-58.11 %
-36.79 %
+45.98 %
+62.01 %
+6.83 %
-34.69 %
-86.15 %
Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug for the treatment of erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are the main desired properties. Dicot's main strategy is to continuously evaluate industrial partnerships during the development of LIB-01 to take the drug candidate to commercialization.
Read moreMarket cap
711.31M SEK
Turnover
2.77M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
18/2
2026
Annual report '25
30/4
2026
Interim report Q1'26
6/5
2026
General meeting '26
All
Webcasts
Press releases
ShowingAll content types
Dicot Pharma submits new patent application for LIB-01 based on positive phase 2a results showing long-term effect
Dicot Pharma presenterar på Stora Aktiedagarna den 26 november
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools